Pediatric Device Stakeholders

News & Events

CTIP Pediatric Medical Device Grant

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is accepting applications for its annual Pediatric Medical Device Grants.




See details below.


We Are Proud to Announce Our Annual Pediatric Medical Device Grant


Pediatric patients have long been an underserved population in the technology space with many having to deal with ill-fitted medical devices and a lack of access to effective diagnostic or therapeutic devices. CTIP aims to address these unmet needs.

Introducing the Catalyzing Pediatric Innovation (CPI) Grant, CTIP's pediatric medical device competition to assist the development of medical device projects for children. We invite proposals addressing the development of novel devices and technologies for pediatric patients.


Letters of Intent


Letters of intent will be considered by the CPI Grant Committee. Based on the comparative merits of all proposals submitted, the most qualified proposals will be designated as finalists. Finalists will be invited to submit a full application.




  • Up to $25,000-$50,000 per grant will be awarded.
  • 1 year grants.
  • Letter of Intent due May 2, 2021 (see details in linked document).


Eligibility requirements for the Catalyzing Pediatric Innovation (CPI) Grant include the following:

  • Must be a novel pediatric medical device or technology.
  • Medical devices must meet the FDA definition of a medical device.
  • Development of novel drugs and chemical therapies will not be funded. Process improvement and innovations are also not eligible for funding. In addition, fetal devices / technologies (without other pediatric applications) will not be funded.
  • Projects must be a pediatric medical device or technology innovation that leads to improved patient experience, quality, outcomes, or efficiency.
  • Eligible projects must have clear achievable milestones for the funding period with specific metrics or deliverables.
  • Projects should be short in duration with funding intended to last no more than 12 months.
Monday, May 2, 2022 - 00:00

InfraScan announces FDA clearance of the first hand-held diagnostic device for Traumatic Brain Hemorrhage in children

InfraScanner is now the only hand-held device cleared by the FDA to detect Traumatic Brain Hemorrhage in children.


InfraScan, a medical device firm specializing in traumatic brain injury diagnostic products, announced a newly expanded FDA indication today. The expanded indication includes the use of Infrascanner for the detection of traumatic supratentorial hematomas in adults, and now pediatric patients aged 2 years and older.

"We are excited to announce the FDA has granted clearance for the use of the Infrascanner technology in the pediatric population aged 2 years and older. Infrascanner is now the only hand-held device in the U.S. Healthcare Market which is cleared for use in the pediatric population to aid in the diagnosis of patients with a potential traumatic brain hemorrhage”, said Baruch Ben Dor, PhD, president and CEO of InfraScan. “The Infrascanner is a cutting-edge technology that can now be used as an additional asset for clinicians as they follow the PECARN guidelines in their moderate risk pediatric patient's evaluations”.

InfraScan extends its gratitude to Children's Hospital of Philadelphia (CHOP), Boston Children's Hospital, Colorado Children's Hospital, The Division of Global Neurosurgery and Neurology at Duke University, Baylor College of Medicine and Pittsburgh Children's Hospital for their dedicated research which helped lead to this announcement. InfraScan also wishes to recognize the Pennsylvania Pediatric Medical Device Consortium ( and the Childress Institute for Pediatric Trauma ( for their invaluable support during this groundbreaking research.

InfraScan has over 1,000 devices deployed in the US and internationally, including with some of the world's leading adult and pediatric Trauma experts. InfraScan also licensed a variety of patents that apply to hemorrhagic and ischemic stroke detection and brain hemorrhage monitoring.

About InfraScan, Inc.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing and distributing portable brain scanners for Traumatic Brain Injuries (TBI) based on near-infrared (NIR) technologies. The company has received funding from the U.S. Army Medical Materiel Development Activity, U.S. Marine Corps, Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and from the Philadelphia Industrial Development Corporation. For more information visit and follow us @infrascanner.

Five Proposals Receive Seed Funds from CHOP-based Pennsylvania Pediatric Medical Device Consortium to Develop Medical Devices for Children

Published on in CHOP News

The Pennsylvania Pediatric Medical Device Consortium (PPDC) has announced its latest round of seed grants to companies developing medical devices for children. The Consortium chose five projects from ten finalists in a competition to receive seed grants of up to $50,000 each.

The devices are a stabilization device for improved placement of IV catheters and PICC lines, a wearable technology to detect and respond to opioid overdose, an ultrasound device to increase safety of G-tube placement, a tool to improved accuracy of small volume medication measurement, and a bedwetting alert and mitigation system.

Funded by the U.S. Food and Drug Administration and based at Children’s Hospital of Philadelphia (CHOP), the PPDC provides know-how and seed funding to help innovators translate promising ideas into commercialized medical devices for use in children. The PPDC is a collaboration involving CHOP, the McGowan Institute for Regenerative Medicine and SciVelo of the University of Pittsburgh, and the University of Pennsylvania.

The new round of awards is the ninth by the PPDC, following seed grants announced in February 2015January 2016January 2017October 2017July 2018May 2019February 2020, and March 2021.

“We are once again excited to support a new group of novel pediatric medical device projects that have the potential to help children in need,” said Robert J. Levy, MD, attending cardiologist in the Cardiac Center at CHOP, the William J. Rashkind Endowed Chair in Pediatric Cardiology at CHOP and the Consortium’s Principal Investigator. 

SafeBoard, LLC of Youngsville, LA is creating SafeBoard, a patented extremity stabilization device designed to assist in the placement of ultrasound-guided PICC lines and IV catheters in neonates and children. Historically, repeated unsuccessful needle sticks and use of general anesthesia and sedation can be traumatic and dangerous to both the patients and their caregivers. SafeBoard aims to minimize the amount of time it takes to successfully insert a PICC/IV in a child, minimize needed personnel, reduce the use of medications, minimize discomfort, and decrease the rates of catheter-related complications.

Jacob Brenner, MD, PhD of the University of Pennsylvania is developing the DOVE device. Adolescents remain extremely vulnerable to the adverse effects of opioid use and overdose. During an overdose, individuals only have a matter of minutes to receive life-saving measures, including naloxone, an opioid overdose antidote. There is an urgent need for novel solutions that passively monitor respiratory drive and trigger automated responses to reverse an overdose when detected. The DOVE device is a wearable biosensor that senses and responds to critically low respiratory rate by automatically injecting naloxone and/or alerting first responders, a trusted contact, or a naloxone-equipped bystander.

CoapTech, Inc. of Baltimore, MD is developing the Pediatric PUMA-G, which is expected to provide a safer way to place feeding tubes for children. Gastrostomy tubes (G-tubes) provide a path for nutrition delivery directly into the stomach, bypassing the mouth and esophagus, for patients who have difficulty swallowing. Traditional technology used in these procedures cannot “see through” tissue, and G-tube malposition causes acute harm and other complications. The alternative fluoroscopic approach requires the use of ionizing radiation, which presents serious long-term risk of cancer. The use of ultrasound imaging is expected to make the Pediatric PUMA-G safer, timelier, and less costly than conventional G-tube placement methods used in children.

Assure Technologies, LLC of Chapel Hill, NC will receive support for the Precynge device to provide consistently accurate small volume medication measurements critical to pediatric care. Neonatal and early pediatric patients are particularly vulnerable to dosing errors; exposure to potential adverse drug events occurs three times more frequently in pediatric than in adult inpatients. While the majority of IV doses are made in the pharmacy, nurses frequently prepare IV push medications at the bedside for small volumes in neonatal and pediatric patients, especially for high alert medications like narcotics and insulin. The Precynge will provide nurses the same safety systems available in the pharmacy.

Global Continence, Inc. of Atlanta, GA is creating a bedwetting mitigation device. Nocturnal enuresis, or bedwetting, affects 200 million children globally and can impact a child’s self-esteem and behavior. The device will sense moisture and immediately activate a painless neuromodulation system to prevent bedwetting and alert the child and/or parents. The device, the first of its kind, can be used in children of all ages and is expected to prevent the need for long-term treatment of bedwetting.

Applications for PPDC funding opportunities are accepted from throughout the U.S. The Consortium also accepts applications year-round for in-kind services and expert advice.

Annoviant Awarded SBIR Phase II Grant from the NIH

Annoviant Awarded $1.85M SBIR Phase II Grant from the National Institutes of Health

Funding will help drive commercialization of next-generation pulmonary valve conduit for pediatric patients

ATLANTA--()--Annoviant LLC, formerly TGen Tech LLC, today announced that it has been awarded a grant of $1.85 million for two years by the National Institutes of Health (NIH) to help further its development and commercialization of the TxGuard™ pulmonary-valved conduit. This is a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019.

“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support”

The new conduit represents breakthrough technology in conduit replacements for the treatment of congenital heart disease (CHD). Tailored largely toward pediatric patients, the device is designed to resist early degeneration and allows regeneration with host cells, enabling the device to grow with children.

CHD affects approximately 40,000 newborns each year in the U.S. Valve and conduit replacements are needed for absent pulmonary valve, aortic stenosis (Konno procedure, Ross, procedure), double outlet right ventricle (Rastelli operation), extracardiac conduit (Fontan operation), and pulmonary valve replacement (Tetralogy of Fallot).

“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support,” said Ajay Houde, Ph.D., MBA, co-founder and CEO, Annoviant. “The grant funding will enable us to address the clinical and cost challenges associated with treating CHD in children.”

The primary issues currently observed with commercial devices are (a) calcification; (b) thrombosis; and (c) infection. Annually, 40,000 (U.S.) and 1.3 million (global) children are born with CHD, resulting in 4%-6% of neonatal deaths. According to the Centers for Disease Control and Prevention (CDC), there are about 2.9 million CHD patients in the U.S.

Pediatric patients with CHD typically undergo 3 to 5 cardiovascular surgeries over their lifetimes with an estimated total cost of $5.61 billion1 to the U.S. healthcare industry for treatment of CHD patients.

The TxGuard “scaffolding” exhibits clinical advantages over commercial products, specifically its cutting-edge qualities that make it resistant to calcification (plaques), thrombosis, and infection. Its ability to regenerate and grow with patients also is a significant distinguishing benefit.

About Annoviant

Annoviant LLC, formerly TGen Tech LLC, is a medical device company founded in 2018 and currently collaborating with a broad ecosystem, including research institutions and industry partners across the country. Fueled by personal experiences of its co-founders, the company is driven by a passion to make a positive difference in the lives and treatment of congenital heart disease (CHD) patients. The new TxGuard™ portfolio of devices can address the clinical challenges and significantly reduce healthcare costs by eliminating the required repeat surgeries. The company is developing cardiovascular devices for structural heart treatments.

NIH: Research reported in this news release was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under Award Number R44HL147771. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.



Originally published on BusinessWire.


PMD Launchpad

The PPDC is excited to announce a new website for stakeholders of pediatric devices! The website is called the PMD Launchpad ( and will be a common platform for stakeholders to go for both entry-level and advanced information on pediatric medical device development.

The vision is for stakeholders to visit one location for necessary information at any level of device innovation. The website includes helpful Knowledge Centers and Resources for device development, as well as spotlights for pediatric devices and device pioneers, a blog with current topics, and other news and events.

We hope this site will serve an audience beyond just the PPDC where visitors can learn and be directed to other resources for further information. Please visit the site and share with others interested in pediatric device development.

And please follow the PMD Launchpad on LinkedIn and Twitter to be notified of new content!

Little Sparrows Technologies Receives FDA Clearance for an Innovative, Portable Medical Device for Treating Infant Jaundice

Start-up receives FDA 510(k) clearance for bili-hut™ Neonatal Phototherapy System, a cost-effective phototherapy device for treating infant jaundice at home or in a hospital.


Somerville, MA, September 17, 2019 – Little Sparrows Technologies, a neonatal medical device startup committed to promoting the well-being of newborns, announced today it has received 510(k) clearance from the Food and Drug Administration (FDA) for the bili-hut™. The bili-hut is an innovative ultraportable neonatal phototherapy system that leverages a bassinet-like design to treat hyperbilirubinemia, commonly known as neonatal jaundice. The device features a unique curved light emitting diode (LED) illumination canopy that delivers high-intensity blue light phototherapy. This highly portable device allows newborns to effectively undergo jaundice treatment anywhere – at home or in a hospital setting.

“Neonatal jaundice is very common and is often diagnosed when a newborn is almost ready for discharge from the hospital or after the baby is home for a few days, requiring longer hospital stays or readmittance,” said Dr. Donna Brezinski, CEO and founder, Little Sparrow Technologies. “Phototherapy treatment typically occurs in NICUs, which separates newborns from their mothers who are bonding and establishing breast feeding. The bili-hut provides the best possible start for jaundiced babies by enabling treatment at the mother’s side, whether in the hospital or at home.”

Neonatal jaundice is a transitional phenomenon which affects three out of five newborns in their first weeks of life. Jaundice causes a yellow discoloration of the skin and eyes in newborns and typically subsides within a few days. In newborns with severe jaundice, blue light phototherapy is required to prevent irreversible neurologic injury.

Jaundice is also one of the most common diagnoses associated with infant readmission to a hospital in the first month of life. In the United States, it is estimated that 100,000 infants develop severe jaundice, costing the healthcare systems $500M annually for hospital-based care. Hospital phototherapy devices can be daunting for new parents and extended hospital stays are often stressful and expensive.
Invented by Dr. Brezinski, a neonatal-perinatal specialist, the bili-hut is capable of delivering hospital intensity phototherapy at the parent’s bedside in either the postpartum room or at home, presenting a new, innovative and cost-effective approach to addressing the challenges of treating jaundice. With the bili-hut doctors can improve the quality of care for infants by maintaining a close relationship with parents while helping to reduce emergency room visits and readmissions.

The bili-hut will be on display at the Little Sparrows Technologies booth #133 at the 2019 American Academy of Pediatrics National Conference & Exhibition in New Orleans, October 26-28.
For more information on the bili-hut, visit

About Little Sparrows Technologies:

Founded in 2013 by Harvard Medical School affiliated doctors, Little Sparrows Technologies offers an innovative approach for treating jaundice. The bili-hut™ is a cost-effective phototherapy device that uses blue LED lights in a reflective bassinet that is capable of operation on battery power. It is simple to use and collapsible for easy transport. Little Sparrows has received two phases of funding from the NIH’s Small Business Innovation Research (SBIR) program, and The World Health Organization included the bili-hut in its Compendium of Medical Devices for Global Health. Little Sparrows Technologies was the winner of a 2018 Patents for Humanity Award. The company offers solutions to support hospitals, US pediatrician offices and international implementations. For more information, visit


Provides an overview of the FDA's PDC program, of which we are part


Provides guidance regarding device classification, basic regulatory requirements for approval, Quality System regulation, labeling requirements, and medical device reporting



Allows you to search the database of issued U.S. patents


       An institute based at the University of Pittsburgh with a primary focus of the development of technology to address tissue and organ insufficiency.


       A medical device development firm with a commercialization process focused on building value, risk reduction, design for manufacture, and shortening time to market.


A partner organization of the PPDC. NAMSA is a medical research organization providing expert regulatory, laboratory, clinical, and compliance services to medical device and healthcare product manufacturers. 


Provides information about the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, including opportunities to apply for federal funding to support small companies in research and development that has a strong potential for commercialization


Penn Health-Tech unites the University of Pennsylvania’s strengths in Medicine, Engineering, Business and Education to create technologies that address the world’s pressing health care needs.


sciVelo is part of the University of Pittsburgh Innovation Institute accelerating life and health sciences translational research and commercialization.


  • To access the other Pediatric Device Consortia:

National Capital Consortium for Pediatric Device Innovation

Southwest National Pediatric Device Consortium

UCSF-Stanford Pediatric Device Consortium

Consortium for Technology and Innovation in Pediatrics